DopAmide

DopAmide
Clinical data
Other namesL-DopAmide; 3-Hydroxytyrosinamide
Drug classMonoamine precursor; Dopamine receptor agonist
Identifiers
  • 2-amino-3-(3,4-dihydroxyphenyl)propanamide
CAS Number
PubChem CID
ChemSpider
Chemical and physical data
FormulaC9H12N2O3
Molar mass196.206 g·mol−1
3D model (JSmol)
  • C1=CC(=C(C=C1CC(C(=O)N)N)O)O
  • InChI=1S/C9H12N2O3/c10-6(9(11)14)3-5-1-2-7(12)8(13)4-5/h1-2,4,6,12-13H,3,10H2,(H2,11,14)
  • Key:DXOJUCNAHCVBRU-UHFFFAOYSA-N

DopAmide, or L-DopAmide, is a synthetic levodopa (L-DOPA) analogue that can serve as a levodopa and dopamine prodrug and is of potential interest in the treatment of Parkinson's disease.[1][2][3] DopAmide has an amide rather than the carboxyl group of L-DOPA,[2][3] which imparts greater water solubility.[1][2][3] The amide is hydrolyzed back to the acid by aminopeptidase enzymes.[1][2][3]

  1. ^ a b c Kang T, Miao Z, Liu S, Ke B (2021). "Prodrug Strategies in the CNS Drugs: Small Modification Makes Big Improvements". Curr Top Med Chem. 21 (24): 2157–2169. doi:10.2174/1568026621666210727163827. PMID 34315372.
  2. ^ a b c d Urso D, Chaudhuri KR, Qamar MA, Jenner P (November 2020). "Improving the Delivery of Levodopa in Parkinson's Disease: A Review of Approved and Emerging Therapies". CNS Drugs. 34 (11): 1149–1163. doi:10.1007/s40263-020-00769-7. PMID 33146817.
  3. ^ a b c d Atlas D (June 2016). "DopAmide: Novel, Water-Soluble, Slow-Release l-dihydroxyphenylalanine (l-DOPA) Precursor Moderates l-DOPA Conversion to Dopamine and Generates a Sustained Level of Dopamine at Dopaminergic Neurons". CNS Neurosci Ther. 22 (6): 461–467. doi:10.1111/cns.12518. PMC 6492885. PMID 26861609.